Release of triple-combo diabetes drugs imminent
By Kim, Jin-Gu | translator Kim, Jung-Ju
23.07.06 12:10:53
가나다라
0
Daewon Pharmaceutical and Hanmi Pharmarcuetical applies for the reimbursement of their 'stagliptin+dapagliflozin+metformin’ combination
Only 2 companies granted approval for triple combination therapy… in contrast to the 96 companies that own indications as dual combination therapy
"Challenging development process, impurity issues... Expansion of market expected in the long-term"
The release of the ‘triple combination therapies' appear to be in sight. However, unlike the 2-drug combos that are already in fierce competition even in the pre-release stage, industry interest in 3-drug combos is currently at best lukewarm.
The pharmaceutical industry pointed to the relatively challenging development environment for triple combination drugs as well as the impurity issues that exist. Nevertheless, there are predictions that in the long term, the paradigm for antidiabetic combos will shift from dual therapy to triple therapy combinations.
96 companies own 100 2-drug combos vs. 2 companies own 7 3-drug combos
According to industry sources on
Kim, Jin-Gu(kjg@dailypharm.com)
If you want to see the full article, please JOIN US (click)